Megan Hooton

President, IQVIA Biotech, IQVIA

Search every verified Megan Hooton interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Megan Hooton, president of IQVIA Biotech, appeared on the BioCentury This Week podcast on July 28, 2025, to discuss the state of the biopharma sector in the second half of the year. During the episode, she noted that while some encouraging signals exist—such as companies converting strong data into follow-on capital and increased M&A activity—the IPO market remains closed, and concerns about U.S. drug pricing and FDA stability persist. Hooton emphasized the importance of improving clinical development decision-making, particularly in Phase 2 trials, where success rates have hovered around 30% at the industry level. She advocated for faster go/no-go decisions and greater use of technology to increase average Phase 2 success rates, noting that drug development currently takes about 13 years from patent filing to patient availability. Hooton also highlighted growth in cell and gene therapy clinical trials, stating that industry-sponsored trials in this area have more than tripled over the past decade, largely driven by CAR-T therapies. She noted that 76 cell and gene therapies had launched globally by the end of 2023, including 20 launches in the prior two years. Her comments on AI use cases, such as identifying trial sites and patients to address recruitment delays, were described by a fellow podcast participant as aligning with feedback from companies in the industry.